Haima is a pre-clinical stage biotechnology company focused on developing bio-inspired therapies to mitigate bleeding in multiple therapeutic indications including traumatic injury, surgery, and thrombocytopenia. Haima has developed a novel, fully-synthetic nanoparticle-based hemostatic technology called SynthoPlate that mitigates bleeding by acting at the site of injury and amplifying your body’s natural clotting mechanisms.